Micardis (Telmisartan)

Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from binding. This inhibition reduces vasoconstriction and aldosterone secretion, leading to relaxation of blood vessels and decreased blood volume, which together lower systemic blood pressure.

The dose of Micardis is individualized by the prescribing healthcare professional based on the patient’s blood pressure response, renal function, and concomitant medications. The prescriber determines the appropriate strength and titration schedule according to clinical guidelines.

The safety of telmisartan during pregnancy has not been established, and it is generally avoided because of potential fetal toxicity. Limited data are available for breastfeeding; therefore, use is not recommended unless the benefit outweighs the risk and a physician advises.

To place an order, submit an enquiry on the Micardis product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with ACE inhibitors, telmisartan offers similar blood‑pressure reduction but a lower incidence of cough. Compared with other ARBs, it has a long half‑life allowing once‑daily dosing and may provide additional metabolic benefits, though clinical choice depends on individual patient factors.

Micardis tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Micardis is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious adverse reactions associated with telmisartan include angioedema, severe hyperkalemia, and acute renal impairment. Patients should seek immediate medical attention if they experience swelling of the face, lips or throat, rapid heartbeat, or a sudden decrease in urine output.

Micardis is contraindicated in patients with known hypersensitivity to telmisartan or any ARB component. It should also be avoided in individuals with severe hepatic impairment and in those taking aliskiren concomitantly if they have diabetes, due to increased risk of adverse effects.